investorscraft@gmail.com

Intrinsic Value of Alexandria Real Estate Equities, Inc. (ARE)

Previous Close$76.01
Intrinsic Value
Upside potential
Previous Close
$76.01

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Alexandria Real Estate Equities, Inc. (ARE) is a leading real estate investment trust (REIT) specializing in high-quality, collaborative life science and technology campuses. The company focuses on leasing laboratory and office spaces to tenants in the biotechnology, pharmaceutical, and technology sectors, primarily in innovation clusters like Boston, San Francisco, and San Diego. ARE’s revenue model is anchored in long-term triple-net leases, providing stable cash flows while maintaining high occupancy rates due to its premium locations and specialized infrastructure. The company’s market position is strengthened by its strategic focus on mission-critical properties for R&D-driven tenants, creating a competitive moat in a niche but growing segment of the commercial real estate market. By catering to the unique needs of life science firms, ARE has established itself as a landlord of choice, benefiting from secular growth in biotech funding and innovation. Its campuses are designed to foster collaboration, further enhancing tenant retention and demand.

Revenue Profitability And Efficiency

For FY 2024, ARE reported revenue of $3.12 billion, with net income of $323 million and diluted EPS of $1.80. Operating cash flow stood at $1.50 billion, reflecting strong operational efficiency. The absence of capital expenditures suggests a focus on maintaining existing assets rather than aggressive expansion. The company’s ability to generate consistent cash flow underscores its stable lease-based revenue model and disciplined cost management.

Earnings Power And Capital Efficiency

ARE’s earnings power is driven by its high-quality tenant base and long-term lease agreements, which provide predictable income. The company’s capital efficiency is evident in its ability to convert revenue into operating cash flow at a high rate, supporting reinvestment and dividend payouts. The lack of significant capital expenditures indicates a mature portfolio with limited near-term growth capex requirements.

Balance Sheet And Financial Health

ARE’s balance sheet shows $552 million in cash and equivalents against total debt of $12.75 billion, reflecting a leveraged but manageable position typical of REITs. The company’s ability to service debt is supported by stable cash flows from leases. The dividend payout ratio, based on EPS, suggests a commitment to returning capital to shareholders while maintaining financial flexibility.

Growth Trends And Dividend Policy

ARE’s growth is tied to the expansion of the life science and technology sectors, with demand for specialized real estate remaining robust. The company’s dividend policy is shareholder-friendly, with an annual dividend of $5.22 per share, reflecting a focus on income generation. Future growth may hinge on strategic acquisitions or development projects in key innovation hubs.

Valuation And Market Expectations

ARE’s valuation reflects its premium positioning in the life science real estate sector, with investors likely pricing in steady cash flow growth and low vacancy risks. Market expectations appear balanced, considering the company’s niche focus and the long-term growth trajectory of its tenant industries.

Strategic Advantages And Outlook

ARE’s strategic advantages include its specialized asset base, strong tenant relationships, and locations in high-demand innovation clusters. The outlook remains positive, supported by sustained biotech R&D investment and limited competition in its niche. However, macroeconomic factors such as interest rate fluctuations could impact financing costs and valuation multiples.

Sources

10-K, investor presentations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount